SCHEMBL415792

SCHEMBL415792

O=CCc1ccccc1[N+](=O)[O-]

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.60
TSHR P16473 1/20 0.60
HPGD P15428 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 2/20 0.47
LMNA P02545 1/20 0.47
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
POLB P06746 1/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
RECQL P46063 1/20 0.44
ACHE P22303 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH3A1 P30838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29951221 1.00 ALDH1A1 (0.60) ALDH1A1TSHRHPGDSMN1; SMN2HTT
SCHEMBL11002560 0.83 TSHR (0.50) ALDH1A1TSHRHPGDSMN1; SMN2HTT
SCHEMBL28248465 0.82 ALDH1A1 (0.63) ALDH1A1TSHRHPGDSMN1; SMN2HTT
SCHEMBL27554222 0.82 ALDH1A1 (0.58) ALDH1A1TSHRHPGDSMN1; SMN2HTT
SCHEMBL28003371 0.82 ALDH1A1 (0.58) ALDH1A1TSHRHPGDSMN1; SMN2HTT
SCHEMBL10885936 0.82 ALDH1A1 (0.58) ALDH1A1TSHRHPGDSMN1; SMN2HTT
SCHEMBL1802351 0.82 ALDH1A1 (0.58) ALDH1A1TSHRHPGDSMN1; SMN2HTT
SCHEMBL30367918 0.82 ALDH1A1 (0.58) ALDH1A1TSHRHPGDSMN1; SMN2HTT
SCHEMBL1135905 0.82 ALDH1A1 (0.58) ALDH1A1TSHRHPGDSMN1; SMN2HTT
SCHEMBL876143 0.82 ALDH1A1 (0.58) ALDH1A1TSHRHPGDSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 256 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1829872-B1 PROCESSES FOR PRODUCTION OF INDOLE COMPOUNDS NISSAN CHEMICAL IND LTD (JP) 2015-07-29 EP claimed
CN-103275169-A Furostanol saponins and synthesis method thereof OCEAN UNIV CHINA 2013-09-04 CN claimed
CN-103265608-A Solanidine type glycoalkaloid and convergent synthesis method thereof OCEAN UNIV CHINA 2013-08-28 CN claimed
CN-103193858-A Synthetic method of spirosolane glycoalkaloids OCEAN UNIV CHINA 2013-07-10 CN claimed
CN-101468964-B Processes for producing indole compound NISSAN CHEMICAL IND LTD 2011-05-11 CN claimed
US-20100197938-A1 Process for producing indole compoud NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-08-05 US claimed
CN-100577659-C Processes for producing indole compound NISSAN CHEMICAL IND LTD 2010-01-06 CN claimed
CN-101468964-A Processes for producing indole compound NISSAN CHEMICAL IND LTD (JP) 2009-07-01 CN claimed
EP-1829872-A1 PROCESSES FOR PRODUCTION OF INDOLE COMPOUNDS Nissan Chemical Industries, Ltd. (JP) 2007-09-05 EP claimed
CN-1896075-A Processes for producing indole compound NISSAN CHEMICAL IND LTD (JP) 2007-01-17 CN claimed
CN-1646522-A Process for producing indole compound NISSAN CHEMICAL IND LTD (JP) 2005-07-27 CN claimed
EP-0489547-B1 A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof ZENECA LTD (GB) 1998-07-29 EP claimed
EP-0703825-B1 METHOD AND APPARATUS FOR CONDUCTING AN ARRAY OF CHEMICAL REACTIONS ON A SUPPORT SURFACE PROTOGENE LAB INC (US) 1997-07-30 EP claimed
EP-0240659-B2 N-substituted 3,4,5,6-tetrahydrophthalimides and their precursors BASF AG (DE) 1994-10-26 EP claimed
US-5280125-A Chemical process for the preparation of 3-alkylated indole IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-01-18 US claimed
EP-0489547-A1 A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof ZENECA LIMITED (GB) 1992-06-10 EP claimed
EP-0362634-A2 Basic dihydropyridines, process for their preparation and their use as intermediates BAYER AG (DE) 1990-04-11 EP claimed
EP-0240659-A2 N-substituted 3,4,5,6-tetrahydrophthalimides and their precursors BASF Aktiengesellschaft (DE) 1987-10-14 EP claimed
US-3931225-A Process for preparing o-nitrobenzylketones HOFFMANN-LA ROCHE INC. (US) 1976-01-06 US claimed
JP-4266870-A None JP disclosed
EP-3958865-B1 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES BAYER AG (DE) 2025-12-10 EP disclosed
US-12403135-B2 4H-pyrrolo[3,2-c]pyridin-4-one derivatives BAYER AKTIENGESELLSCHAFT (DE) 2025-09-02 US disclosed
US-20250215467-A1 L-THREONINE TRANSALDOLASES AND USES THEREOF UNIVERSITY OF DELAWARE (US) 2025-07-03 US disclosed
WO-2023178318-A2 L-THREONINE TRANSALDOLASES AND USES THEREOF KUNJAPUR ADITYA (US) 2023-09-21 WO disclosed
EP-3700904-B1 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES BAYER AG (DE) 2023-07-19 EP disclosed
CN-116234798-A Sulfamate derivative compounds for the treatment or alleviation of psychotic disorders 生物药品解决方案有限公司 2023-06-06 CN disclosed
US-20220378762-A1 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2022-12-01 US disclosed
CN-114591160-A Method for preparing aryl acetaldehyde from aryl formaldehyde and diaryl ketone 长沙资材科技有限公司 2022-06-07 CN disclosed
US-11339157-B1 4H-pyrrolo[3,2-c]pyridin-4-one derivatives BAYER AKTIENGESELLSCHAFT (DE) 2022-05-24 US disclosed
EP-3958865-A1 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES Bayer Aktiengesellschaft (DE) 2022-03-02 EP disclosed
US-20210179578-A1 OX1 ANTAGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-06-17 US disclosed
US-20210179578-A1 OX1 ANTAGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-06-17 US disclosed
CN-111995577-A Synthetic method of 4-fluoro indazole 3-carbonitrile or derivatives thereof 上海代为化学科技有限公司 2020-11-27 CN disclosed
WO-2020216774-A1 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2020-10-29 WO disclosed
EP-3710435-A1 OX1 ANTAGONISTS Heptares Therapeutics Limited (GB) 2020-09-23 EP disclosed
EP-3700904-A1 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES Bayer AG (DE) 2020-09-02 EP disclosed
CN-106507667-B Sulfamate derivatives for the prevention or treatment of epilepsy 比皮艾思药物研发有限公司 2020-01-24 CN disclosed
US-20180346484-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE DEUTSCHLAND (DE) 2018-12-06 US disclosed
EP-3307067-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES Merck Sharp & Dohme Corp. (US) 2018-04-18 EP disclosed
US-9879033-B2 Modulators of 5-HT receptors and methods of use thereof AbbVie Deutschland GmbH & Co. KG (DE) 2018-01-30 US disclosed
CN-107311829-A The synthetic method of fragrant second aldehyde compound 凯莱英生命科学技术(天津)有限公司 2017-11-03 CN disclosed
US-9745280-B2 Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient SNU R&DB FOUNDATION (KR) 2017-08-29 US disclosed
EP-2571353-B1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE INC (US) 2017-08-09 EP disclosed
CN-106507667-A For preventing or treating the sulfamate derivatives of epilepsy 比皮艾思药物研发有限公司 2017-03-15 CN disclosed
EP-2788359-B1 COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS RES TRIANGLE INST (US) 2017-03-01 EP disclosed
WO-2016200717-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2016-12-15 WO disclosed
US-20160340331-A1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT SNU R&DB FOUNDATION (KR) 2016-11-24 US disclosed
WO-2016164412-A1 HYPOXIA-INDUCIBLE FACTOR 1 (HIF-1) INHIBITORS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2016-10-13 WO disclosed
US-20160207938-A1 QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2016-07-21 US disclosed
CN-105481864-A Modulators of 5-HT receptors and methods of use thereof ABBOTT GMBH & CO KG ABBOTT LAB 2016-04-13 CN disclosed
US-20160096851-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE INC. 2016-04-07 US disclosed
EP-2989106-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS Beigene, Ltd. (KY) 2016-03-02 EP disclosed
US-9273013-B2 Quinazoline derivatives JANSSEN PHARMACEUTICA NV (BE) 2016-03-01 US disclosed
CN-102712643-B Modulators of 5-HT receptors and methods of use thereof ABBVIE (US) 2015-12-16 CN disclosed
US-9187483-B2 Modulators of 5-HT receptors and methods of use thereof ABBVIE INC. (US) 2015-11-17 US disclosed
CN-104860951-A Modulators of 5-HT receptors and methods of use thereof AbbVie Deutschland GmbH and Co KG 2015-08-26 CN disclosed
EP-1829872-B1 PROCESSES FOR PRODUCTION OF INDOLE COMPOUNDS NISSAN CHEMICAL IND LTD (JP) 2015-07-29 EP disclosed
CN-103265608-B Solanidine type glycoalkaloid and convergent synthesis method thereof OCEAN UNIV CHINA 2015-04-22 CN disclosed
US-8969573-B2 Compounds for the inhibition of cellular proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-03-03 US disclosed
US-8969573-B2 Compounds for the inhibition of cellular proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-03-03 US disclosed
EP-2641907-B1 Preparation of modulators of 5-HT receptors ABBVIE INC (US) 2015-01-28 EP disclosed
US-8933067-B2 Pyrido and pyrimidopyrimidine derivatives as anti-profilerative agents JANSSEN PHARMACEUTICA NV (BE) 2015-01-13 US disclosed
WO-2014173289-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS BEIGENE, LTD. (KY) 2014-10-30 WO disclosed
US-8865704-B2 Wnt pathway antagonists SIENA BIOTECH S.P.A. (IT) 2014-10-21 US disclosed
US-8865704-B2 Wnt pathway antagonists SIENA BIOTECH S.P.A. (IT) 2014-10-21 US disclosed
US-8865704-B2 Wnt pathway antagonists SIENA BIOTECH S.P.A. (IT) 2014-10-21 US disclosed
US-8846951-B2 Modulators of 5-HT receptors and methods of use thereof ABBVIE INC. (US) 2014-09-30 US disclosed
US-8772272-B2 Pyrido-and pyrimidopyrimidine derivatives as anti-proliferative agents JANSSEN PHARMACEUTICA NV (BG) 2014-07-08 US disclosed
EP-2641907-A1 Preparation of modulators of 5-HT receptors AbbVie Inc. (US) 2013-09-25 EP disclosed
US-20130231353-A1 PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROFILERATIVE AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2013-09-05 US disclosed
CN-103275133-A Synthetic method of beta-D-oligomannuronate or glucoside OCEAN UNIV CHINA 2013-09-04 CN disclosed
CN-103275169-A Furostanol saponins and synthesis method thereof OCEAN UNIV CHINA 2013-09-04 CN disclosed
CN-103265608-A Solanidine type glycoalkaloid and convergent synthesis method thereof OCEAN UNIV CHINA 2013-08-28 CN disclosed
US-20130178505-A1 Compounds for the Inhibition of Cellular Proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-07-11 US disclosed
US-20130178505-A1 Compounds for the Inhibition of Cellular Proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-07-11 US disclosed
US-20130178624-A1 QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2013-07-11 US disclosed
EP-2485728-B1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH SPA (IT) 2013-07-10 EP disclosed
EP-2485728-B1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH SPA (IT) 2013-07-10 EP disclosed
CN-103193858-A Synthetic method of spirosolane glycoalkaloids OCEAN UNIV CHINA 2013-07-10 CN disclosed
EP-2585459-A1 ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF Chiesi Farmaceutici S.p.A. (IT) 2013-05-01 EP disclosed
EP-2585453-A2 COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION President and Fellows of Harvard College (US) 2013-05-01 EP disclosed
EP-2432783-B1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LAB (US) 2013-05-01 EP disclosed
EP-2576700-A1 PIGMENT DISPERSIONS, RELATED COATING COMPOSITIONS AND COATED SUBSTRATES PPG Industries Ohio, Inc. (US) 2013-04-10 EP disclosed
EP-2571353-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF AbbVie Inc. (US) 2013-03-27 EP disclosed
US-8394786-B2 Quinazoline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2013-03-12 US disclosed
US-8394955-B2 2,4 (4,6) pyrimidine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2013-03-12 US disclosed
EP-2485728-A1 WNT PATHWAY ANTAGONISTS Siena Biotech S.p.a. (IT) 2012-08-15 EP disclosed
US-20120196851-A1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH S.P.A. (IT) 2012-08-02 US disclosed
US-20120196851-A1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH S.P.A. (IT) 2012-08-02 US disclosed
US-20120196851-A1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH S.P.A. (IT) 2012-08-02 US disclosed
WO-2012078956-A1 POLYMERIC SUBSTRATES HAVING A THIN METAL FILM AND FINGERPRINT RESISTANT CLEAR COATING DEPOSITED THEREON AND RELATED METHODS PPG INDUSTRIES OHIO, INC. (US) 2012-06-14 WO disclosed
US-20120148846-A1 COLOR PLUS CLEAR COATING SYSTEMS EXHIBITING DESIRABLE APPEARANCE AND FINGERPRINT RESISTANCE PROPERTIES AND RELATED METHODS PPG INDUSTRIES OHIO, INC. (US) 2012-06-14 US disclosed
WO-2012078953-A1 COLOR PLUS CLEAR COATING SYSTEMS EXHIBITING DESIRABLE APPEARANCE AND FINGERPRINT RESISTANCE PROPERTIES AND RELATED METHODS PPG INDUSTRIES OHIO, INC. (US) 2012-06-14 WO disclosed
US-8148388-B2 2,4 (4,6) pyrimidine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2012-04-03 US disclosed
EP-2432783-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF Abbott Laboratories (US) 2012-03-28 EP disclosed
US-20120065395-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES FREYNE EDDY JEAN EDGARD (BE) 2012-03-15 US disclosed
WO-2012006068-A2 COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-01-12 WO disclosed
WO-2011161018-A1 ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2011-12-29 WO disclosed
WO-2011146089-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2011-11-24 WO disclosed
WO-2011134067-A1 NOVEL AMINO ACID MOLECULE AND USES THEREOF 6570763 CANADA INC. (CA) 2011-11-03 WO disclosed
EP-2375899-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF Array Biopharma, Inc. (US) 2011-10-19 EP disclosed
US-20110118473-A1 PROCESS FOR CONVERTING 9-DIHYDRO-13ACETYLBACCATIN III PACLITAXEL AND DOCETAXEL 6570763 CANADA INC. (CA) 2011-05-19 US disclosed
US-20110118231-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2011-05-19 US disclosed
CN-101468964-B Processes for producing indole compound NISSAN CHEMICAL IND LTD 2011-05-11 CN disclosed
CN-101468964-B Processes for producing indole compound NISSAN CHEMICAL IND LTD 2011-05-11 CN disclosed
WO-2011042145-A1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH S.P.A. (IT) 2011-04-14 WO disclosed
WO-2011042145-A1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH S.P.A. (IT) 2011-04-14 WO disclosed
US-7847111-B2 Semi-synthetic route for the preparation of paclitaxel, docetaxel, and 10-deacetylbaccatin III from 9-dihydro-13-acetylbaccatin III CANADA INC. (CA) 2010-12-07 US disclosed
WO-2010135560-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2010-11-25 WO disclosed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
US-20100298292-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2010-11-25 US disclosed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-7799772-B2 tyrosine kinase inhibitors such as 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro, used for treating hyper proliferative disorders such as atherosclerosis, restenosis and cancer JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-21 US disclosed
US-20100197938-A1 Process for producing indole compoud NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-08-05 US disclosed
US-20100197938-A1 Process for producing indole compoud NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-08-05 US disclosed
WO-2010080864-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2010-07-15 WO disclosed
US-20100173913-A1 PYRIDO-AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROLIFERATIVE AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-07-08 US disclosed
US-20100160310-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2010-06-24 US disclosed
EP-2183234-A1 PROCESS FOR CONVERTING 9-DIHYDRO-13-ACETYLBACCATIN III INTO DOCETAXEL OR PACLITAXEL 6570763 Canada Inc. (CA) 2010-05-12 EP disclosed
US-20100105668-A1 Quinazoline derivatives FREYNE EDDY JEAN EDGARD 2010-04-29 US disclosed
US-7648975-B2 Macrocyclic quinazoline derivatives as antiproliferative agents JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-19 US disclosed
US-7648975-B2 Macrocyclic quinazoline derivatives as antiproliferative agents JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-19 US disclosed
CN-100577659-C Processes for producing indole compound NISSAN CHEMICAL IND LTD 2010-01-06 CN disclosed
CN-100577659-C Processes for producing indole compound NISSAN CHEMICAL IND LTD 2010-01-06 CN disclosed
EP-2114958-A1 INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS Vertex Pharmceuticals Incorporated (US) 2009-11-11 EP disclosed
EP-1829872-A4 PROCESSES FOR PRODUCTION OF INDOLE COMPOUNDS NISSAN CHEMICAL IND LTD (JP) 2009-08-19 EP disclosed
WO-2009090548-A2 3-AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS GLENMARK PHARMACEUTICALS, S.A. (US) 2009-07-23 WO disclosed
CN-101468964-A Processes for producing indole compound NISSAN CHEMICAL IND LTD (JP) 2009-07-01 CN disclosed
CN-101468964-A Processes for producing indole compound NISSAN CHEMICAL IND LTD (JP) 2009-07-01 CN disclosed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN disclosed
US-7550410-B2 Method and apparatus for combinatorial chemistry FOOTE ROBERT S 2009-06-23 US disclosed
EP-2029563-A1 SEMI-SYNTHETIC ROUTE FOR THE PREPARATION OF PACLITAXEL, DOCETAXEL AND 10-DEACETYLBACCATIN III FROM 9-DIHYDRO-13-ACETYLBACCATIN III 6570763 Canada Inc. (CA) 2009-03-04 EP disclosed
WO-2009023967-A1 PROCESS FOR CONVERTING 9-DIHYDRO-13-ACETYLBACCATIN III INTO DOCETAXEL OR PACLITAXEL 6570763 CANADA INC. (CA) 2009-02-26 WO disclosed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP disclosed
EP-2004716-A2 METHOD OF MAKING URETHANE BASED FLUORINATED MONOMERS 3M Innovative Properties Company (US) 2008-12-24 EP disclosed
WO-2008106139-A1 INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-04 WO disclosed
EP-1928845-A2 AMINODIAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS Array Biopharma, Inc. (US) 2008-06-11 EP disclosed
EP-1917269-A2 INHIBITORS OF SERINE PROTEASES Vertex Pharmaceuticals Incorporated (US) 2008-05-07 EP disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
WO-2007143839-A1 SEMI-SYNTHETIC ROUTE FOR THE PREPARATION OF PACLITAXEL, DOCETAXEL AND 10-DEACETYLBACCATIN III FROM 9-DIHYDRO-13-ACETYLBACCATIN III 6570763 CANADA INC. (CA) 2007-12-21 WO disclosed
US-20070293687-A1 SEMI-SYNTHETIC ROUTE FOR THE PREPARATION OF PACLITAXEL, DOCETAXEL, AND 10-DEACETYLBACCATIN III FROM 9-DIHYDRO-13-ACETYLBACCATIN III 6570763 CANADA INC. (CA) 2007-12-20 US disclosed
WO-2007124263-A2 METHOD OF MAKING URETHANE BASED FLUORINATED MONOMERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-11-01 WO disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed
US-20070244289-A1 METHOD OF MAKING URETHANE BASED FLUORINATED MONOMERS 3M INNOVATIVE PROPERTIES COMPANY 2007-10-18 US disclosed
EP-1829872-A1 PROCESSES FOR PRODUCTION OF INDOLE COMPOUNDS Nissan Chemical Industries, Ltd. (JP) 2007-09-05 EP disclosed
US-20070087367-A1 METHOD AND APPARATUS FOR COMBINATORIAL CHEMISTRY FOOTE ROBERT S 2007-04-19 US disclosed
WO-2007040840-A2 AMINODIAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS ARRAY BIOPHARMA INC. (US) 2007-04-12 WO disclosed
US-20070083053-A1 Process for producing indole compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2007-04-12 US disclosed
US-20070083053-A1 Process for producing indole compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2007-04-12 US disclosed
US-20070078132-A1 tyrosine kinase inhibitors such as 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro, used for treating hyper proliferative disorders such as atherosclerosis, restenosis and cancer JANSSEN-CILAG (FR) 2007-04-05 US disclosed
EP-1761486-A1 PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES Merck Patent GmbH (DE) 2007-03-14 EP disclosed
WO-2007025307-A2 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-03-01 WO disclosed
US-7179591-B2 Method and apparatus for combinatorial chemistry Foote, Robert S. (US) 2007-02-20 US disclosed
CN-1896075-A Processes for producing indole compound NISSAN CHEMICAL IND LTD (JP) 2007-01-17 CN disclosed
CN-1896075-A Processes for producing indole compound NISSAN CHEMICAL IND LTD (JP) 2007-01-17 CN disclosed
CN-1286810-C 2-acyl indol derivatives and their use as anti-tumour agents BAKST HEALTH AG (CH) 2006-11-29 CN disclosed
CN-1286832-C Process for producing indole compound NISSAN CHEMICAL IND LTD (JP) 2006-11-29 CN disclosed
CN-1286832-C Process for producing indole compound NISSAN CHEMICAL IND LTD (JP) 2006-11-29 CN disclosed
JP-2006176500-A PROCESS FOR PRODUCING INDOLE COMPOUND NISSAN CHEM IND LTD 2006-07-06 JP disclosed
WO-2006057354-A1 PROCESSES FOR PRODUCTION OF INDOLE COMPOUNDS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2006-06-01 WO disclosed
WO-2006000288-A1 PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2006-01-05 WO disclosed
CN-1646522-A Process for producing indole compound NISSAN CHEMICAL IND LTD (JP) 2005-07-27 CN disclosed
CN-1646522-A Process for producing indole compound NISSAN CHEMICAL IND LTD (JP) 2005-07-27 CN disclosed
EP-1048658-B1 ALICYCLIC ACYLATED HETEROCYCLIC DERIVATIVES SANKYO CO (JP) 2005-06-15 EP disclosed
EP-1159285-B1 METHODS AND COMPOSITIONS FOR ECONOMICALLY SYNTHESIZING AND ASSEMBLING LONG DNA SEQUENCES METRIGEN INC (US) 2005-05-25 EP disclosed
JP-2005035991-A METHOD FOR PRODUCING INDOLE COMPOUND NISSAN CHEM IND LTD 2005-02-10 JP disclosed
US-20050009092-A1 Method and apparatus for conducting an array of chemical reactions on a support surface BRENNAN THOMAS M (US) 2005-01-13 US disclosed
WO-2005000812-A1 PROCESS FOR PRODUCING INDOLE COMPOUND NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2005-01-06 WO disclosed
EP-0831094-B1 FUSED POLYCYCLIC HETEROCYCLE DERIVATIVES EISAI CO LTD (JP) 2004-12-08 EP disclosed
EP-1076677-B1 CERAMER COMPOSITION HAVING ABRASION AND STAIN RESISTANT CHARACTERISTICS 3M INNOVATIVE PROPERTIES CO (US) 2004-10-27 EP disclosed
CN-1142932-C N,N-dimethyl-1-t-butoxycarbonyl-4-phenylpiperidine-4-carboxamide ������������ʽ���� 2004-03-24 CN disclosed
JP-2004083559-A PRODUCTION PROCESS FOR INDOLE COMPOUND NISSAN CHEM IND LTD 2004-03-18 JP disclosed
US-20030232382-A1 Method and apparatus for performing large numbers of reactions using array assembly BRENNAN THOMAS M (US) 2003-12-18 US disclosed
US-6632641-B1 Filling wells in solid supports with reactants; releasing polynucleotides into solution in wells; amplification METRIGEN, INC. 2003-10-14 US disclosed
WO-2003082860-A1 PROCESSES FOR PRODUCING INDOLE COMPOUND NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2003-10-09 WO disclosed
US-20030186226-A1 Methods and compositions for economically synthesizing and assembling long DNA sequences MOLINARI, ROBERT J., PH.D. AS COLLATERAL AGENT 2003-10-02 US disclosed
CN-1121398-C Alicyclic acylated heterocyclic derivatives SANKYO CO (JP) 2003-09-17 CN disclosed
CN-1431997-A 2-acylindole derivatives and their use as antitumor agents BAKST HEALTH AG (CH) 2003-07-23 CN disclosed
US-6589726-B1 Reacting surface with reagent to form a hydrophilic surface; coating with a photoresist substance; exposing to light and developing to form a pattern; reacting with a second reagent to form hydrophobic sites and removing photoresist coat; METRIGEN, INC. 2003-07-08 US disclosed
US-20030068643-A1 Methods and compositions for economically synthesizing and assembling long DNA sequences BRENNAN THOMAS M (US) 2003-04-10 US disclosed
US-6448247-B1 TACHYKININ RECEPTOR ANTAGONIST; ESPECIALLY TO THE RECEPTORS FOR SUBSTANCE P (WHICH RECEPTORS ARE GENERALLY REFERRED TO AS ?NEUROKININ 1 RECEPTORS?) SANKYO COMPANY, LIMITED (JP) 2002-09-10 US disclosed
EP-1235932-A2 METHOD AND APPARATUS FOR PERFORMING LARGE NUMBERS OF REACTIONS USING ARRAY ASSEMBLY Protogene Laboratories, Inc. (US) 2002-09-04 EP disclosed
EP-0869126-B1 Dithiolan derivatives, their preparation and their therapeutic effect SANKYO CO (JP) 2002-07-31 EP disclosed
US-6358601-B1 POLYMER MATRIX, SURFACE TREATED INORGANIC OXIDE IN MATRIX AND ANTISTATIC AGENT WITH NONIONIC SURFACTANT 3M INNOVATIVE PROPERTIES COMPANY 2002-03-19 US disclosed
WO-2002016023-A2 METHOD AND APPARATUS FOR IN SITU SYNTHESIS ON A SOLID SUPPORT PROTOGENE LABORATORIES, INC. (US) 2002-02-28 WO disclosed
EP-0776893-B1 Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 SANKYO CO (JP) 2002-02-27 EP disclosed
EP-1163298-A1 CERAMER COMPOSITION AND COMPOSITE COMPRISING FREE RADICALLY CURABLE FLUOROCHEMICAL COMPONENT 3M Innovative Properties Company (US) 2001-12-19 EP disclosed
EP-1159285-A1 METHODS AND COMPOSITIONS FOR ECONOMICALLY SYNTHESIZING AND ASSEMBLING LONG DNA SEQUENCES Protogene Laboratories, Inc. (US) 2001-12-05 EP disclosed
US-6313164-B1 TO ENHANCE THE ACTIVITY OF GLUTATHIONE RECLUCTASE; FOR THERAPY AND PROPHYLAXIS OF CARTARACTS SANKYO COMPANY, LIMITED (JP) 2001-11-06 US disclosed
US-20010029028-A1 Method and apparatus for combinatorial chemistry FOOTE, ROBERT S. 2001-10-11 US disclosed
EP-1140828-A1 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS Pfizer Limited (GB) 2001-10-10 EP disclosed
US-6288059-B1 ANTIASTHMATIC, ANTIALLERGEN AGENTS; URINARY INCONTINENCE; NATURAL KILLER CELL RECEPTOR AND TACHYKININ ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 2001-09-11 US disclosed
CN-1067686-C Fused polycyclic heterocycle derivatives EISAI CO LTD (JP) 2001-06-27 CN disclosed
US-6238798-B1 CURABLE CERAMER COMPOSITION PROVIDING HARDNESS, ABRASION RESISTANCE, STAIN, OIL AND/OR WATER REPELLENCY; OPTICS 3M INNOVATIVE PROPERTIES COMPANY 2001-05-29 US disclosed
WO-2001027327-A2 METHOD AND APPARATUS FOR PERFORMING LARGE NUMBERS OF REACTIONS USING ARRAY ASSEMBLY PROTOGENE LABORATORIES, INC. (US) 2001-04-19 WO disclosed
EP-1087963-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 Chiron Corporation (US) 2001-04-04 EP disclosed
US-6210894-B1 Method and apparatus for conducting an array of chemical reactions on a support surface PROTOGENE LABORATORIES, INC. 2001-04-03 US disclosed
WO-2001018082-A1 RETROREFLECTIVE ARTICLES INCLUDING A CURED CERAMER COMPOSITE COATING 3M INNOVATIVE PROPERTIES COMPANY (US) 2001-03-15 WO disclosed
EP-1082497-A1 RETROREFLECTIVE ARTICLES INCLUDING A CURED CERAMER COMPOSITE COATING HAVING ABRASION AND STAIN RESISTANT CHARACTERISTICS 3M Innovative Properties Company (US) 2001-03-14 EP disclosed
EP-1070710-A2 Dithiolan derivatives, their preparation and their therapeutic effect Sankyo Company Limited (JP) 2001-01-24 EP disclosed
US-6159967-A Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use SANKYO COMPANY, LIMITED (JP) 2000-12-12 US disclosed
WO-2000066259-A1 METHOD AND APPARATUS FOR COMBINATORIAL CHEMISTRY UT-BATTELLE, LLC (US) 2000-11-09 WO disclosed
EP-1048658-A1 ALICYCLIC ACYLATED HETEROCYCLIC DERIVATIVES Sankyo Company Limited (JP) 2000-11-02 EP disclosed
WO-2000053617-A1 METHODS AND COMPOSITIONS FOR ECONOMICALLY SYNTHESIZING AND ASSEMBLING LONG DNA SEQUENCES PROTOGENE LABORATORIES, INC. (US) 2000-09-14 WO disclosed
WO-2000050517-A1 CERAMER COMPOSITION AND COMPOSITE COMPRISING FREE RADICALLY CURABLE FLUOROCHEMICAL COMPONENT 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-08-31 WO disclosed
WO-2000039089-A1 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS PFIZER LIMITED (GB) 2000-07-06 WO disclosed
US-6013663-A CATARACT THERAPY OR PREVENTION SANKYO COMPANY, LIMITED (JP) 2000-01-11 US disclosed
WO-1999065897-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 1999-12-23 WO disclosed
US-5985551-A Method and apparatus for conducting an array of chemical reactions on a support surface PROTOGENE LABORATORIES, INC. (US) 1999-11-16 US disclosed
WO-1999057375-A1 RETROREFLECTIVE ARTICLES INCLUDING A CURED CERAMER COMPOSITE COATING HAVING ABRASION AND STAIN RESISTANT CHARACTERISTICS 3M INNOVATIVE PROPERTIES COMPANY (US) 1999-11-11 WO disclosed
US-5952335-A ANTITUMOR AGENTS EISAI CO., LTD. (JP) 1999-09-14 US disclosed
CN-1208035-A Dithiolan derivatives, their preparation and their therapeutic effect SANKYO CO (JP) 1999-02-17 CN disclosed
EP-0869126-A1 Dithiolan derivatives, their preparation and their therapeutic effect Sankyo Company Limited (JP) 1998-10-07 EP disclosed
EP-0489547-B1 A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof ZENECA LTD (GB) 1998-07-29 EP disclosed
CN-1185781-A Fused Polycyclic Heterocyclic Derivatives EISAI CO LTD (JP) 1998-06-24 CN disclosed
EP-0831094-A1 FUSED POLYCYCLIC HETEROCYCLE DERIVATIVES Eisai Co., Ltd. (JP) 1998-03-25 EP disclosed
CN-1157286-A N,N-dimethyl-1-t-butoxycarbonyl-4-phenylpiperidine-4-carboxamide SANKYO CO (JP) 1997-08-20 CN disclosed
EP-0703825-B1 METHOD AND APPARATUS FOR CONDUCTING AN ARRAY OF CHEMICAL REACTIONS ON A SUPPORT SURFACE PROTOGENE LAB INC (US) 1997-07-30 EP disclosed
EP-0776893-A1 Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 SANKYO COMPANY LIMITED (JP) 1997-06-04 EP disclosed
EP-0703825-A1 METHOD AND APPARATUS FOR CONDUCTING AN ARRAY OF CHEMICAL REACTIONS ON A SUPPORT SURFACE PROTOGENE LAB INC (US) 1996-04-03 EP disclosed
CN-1030739-C Method for selectively coating metal surface, method for forming circuit pattern from metal surface and photosensitive emulsion used therefor GRACE W R & CO (US) 1996-01-17 CN disclosed
US-5474796-A Immobilization PROTOGENE LABORATORIES, INC. (US) 1995-12-12 US disclosed
WO-1994027719-A1 METHOD AND APPARATUS FOR CONDUCTING AN ARRAY OF CHEMICAL REACTIONS ON A SUPPORT SURFACE PROTOGENE LABORATORIES, INC. (US) 1994-12-08 WO disclosed
US-5280125-A Chemical process for the preparation of 3-alkylated indole IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-01-18 US disclosed
US-5280125-A Chemical process for the preparation of 3-alkylated indole IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-01-18 US disclosed
EP-0512074-A4 MOLECULES WITH ANTIBODY COMBINING SITES THAT CATALYSE HYDROLYSIS REACTIONS 1993-07-14 EP disclosed
US-5164499-A Nitroaryl carbonyl compounds, nitrodihydroaryl carbonyl intermediates thereto, and processes E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-11-17 US disclosed
EP-0512074-A1 MOLECULES WITH ANTIBODY COMBINING SITES THAT CATALYSE HYDROLYSIS REACTIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1992-11-11 EP disclosed
JP-H04266870-A CHEMICAL PRODUCTION IMPERIAL CHEM IND PLC <ICI> 1992-09-22 JP disclosed
EP-0489547-A1 A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof ZENECA LIMITED (GB) 1992-06-10 EP disclosed
EP-0489547-A1 A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof ZENECA LIMITED (GB) 1992-06-10 EP disclosed
CN-1054836-A Automatic deposition emulsion and the method for the metal surface being carried out selective protection with this emulsion GRACE W R & CO (US) 1991-09-25 CN disclosed
WO-1991011512-A1 MOLECULES WITH ANTIBODY COMBINING SITES THAT CATALYSE HYDROLYSIS REACTIONS SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1991-08-08 WO disclosed
US-4912220-A Mixing a nitroaryl compound with an unsaturated silane under anhydrous conditions; adding a fluoride compound and an electrophilic compound E. I. DU PONT DE NEMOURS AND COMPANY (US) 1990-03-27 US disclosed
US-4810282-A 3-ORTHO-(ISOXAZOLYL,ISOTHIAZOLYL, PYRAZOLYL,THIADIAZOLYL, OXADIAZOLYL AND TRIAZOLYL BENZENESULFONUREYLENE-1,2,4-TRIAZOLES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-03-07 US disclosed
US-4743690-A NITROARYL COMPOUND, SILANE, FLUORO ONIUM COMPOUND, BROMIDE E. I. DU PONT DE NEMOURS AND COMPANY (US) 1988-05-10 US disclosed
EP-0083975-B1 HERBICIDAL SULFONAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-11-19 EP disclosed
US-4695311-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-09-22 US disclosed
US-4659862-A Process of preparing nitrodihydroaryl carbonyl compounds E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-04-21 US disclosed
US-4606755-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1986-08-19 US disclosed
US-4536391-A REACTING A PLASMIN HEAVY CHAIN WITH UROKINASE IN THE PRESENCE OF A COUPLING AGENT OTSUKA PHARMACEUTICAL CO. (JP) 1985-08-20 US disclosed
US-4511392-A N--/PYRIMIDIN-2-YLAMINOCARBENYL/-HETERO-SUBSTITUETED BENZENSESULFO E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-04-16 US disclosed
US-4454337-A Semicarbazide intermediates for preparing 4-substituted indoles SMITHKLINE BECKMAN CORPORATION (US) 1984-06-12 US disclosed
EP-0109653-A2 Process for preparing urokinase complex OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-05-30 EP disclosed
EP-0083975-A2 Herbicidal sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1983-07-20 EP disclosed
US-4394514-A Processes for preparing 4-substituted indoles SMITHKLINE BECKMAN CORPORATION (US) 1983-07-19 US disclosed
US-4333930-A TREATMENT OF CENTRAL NERVOUS DISORDERS, ANALGESICS, ANTIDEPRESSANTS LABORATOIRES SARGET (FR) 1982-06-08 US disclosed
US-4127581-A Method for the preparation of 3-phenyl-5-substituted-4(1H)-pyridones ELI LILLY AND COMPANY (US) 1978-11-28 US disclosed
US-3979410-A Intermediate α-acyl-β-dialkylamino-2-nitrostyrenes HOFFMANN-LA ROCHE INC. (US) 1976-09-07 US disclosed
US-3979410-A Intermediate α-acyl-β-dialkylamino-2-nitrostyrenes HOFFMANN-LA ROCHE INC. (US) 1976-09-07 US disclosed
US-3931225-A Process for preparing o-nitrobenzylketones HOFFMANN-LA ROCHE INC. (US) 1976-01-06 US disclosed
US-3931225-A Process for preparing o-nitrobenzylketones HOFFMANN-LA ROCHE INC. (US) 1976-01-06 US disclosed
US-3931225-A Process for preparing o-nitrobenzylketones HOFFMANN-LA ROCHE INC. (US) 1976-01-06 US disclosed
US-3931225-A Process for preparing o-nitrobenzylketones HOFFMANN-LA ROCHE INC. (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (25 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178624-A1 QUINAZOLINE DERIVATIVES NR1H2, NR1H3, NR3C2 ALDH1A1 2807/4885TSHR 496/4885HPGD 344/4885
US-20070293687-A1 SEMI-SYNTHETIC ROUTE FOR THE PREPARATION OF PACLITAXEL, DOCETAXEL, AND 10-DEACETYLBACCATIN III FROM 9-DIHYDRO-13-ACETYLBACCATIN III H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KAT5, KYAT3 ALDH1A1 3256/4885TSHR 4282/4885HPGD 1598/4885
US-20070078132-A1 tyrosine kinase inhibitors such as 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro, used for treating hyper proliferative disorders such as atherosclerosis, restenosis and cancer NR1H3, NR1H2, ERBB2 ALDH1A1 3804/4885TSHR 1124/4885HPGD 589/4885
US-20220378762-A1 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES EGFR, ERBB2, ERBB4 ALDH1A1 1255/4885TSHR 2270/4885HPGD 235/4885
US-20160096851-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR3A, HTR5A, HTR3C ALDH1A1 971/4885TSHR 136/4885HPGD 504/4885
US-20100298292-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR3A, HTR5A, HTR3C ALDH1A1 971/4885TSHR 136/4885HPGD 504/4885
US-20130231353-A1 PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROFILERATIVE AGENTS NR4A1, CYP2J2, NR3C2 ALDH1A1 1357/4885TSHR 1741/4885HPGD 273/4885
US-12403135-B2 4H-pyrrolo[3,2-c]pyridin-4-one derivatives EGFR, ERBB2, ERBB4 ALDH1A1 1255/4885TSHR 2270/4885HPGD 235/4885
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 ALDH1A1 1302/4885TSHR 2071/4885HPGD 1775/4885
US-20110118231-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR3A, HTR5A, HTR3C ALDH1A1 971/4885TSHR 136/4885HPGD 504/4885
US-20210179578-A1 OX1 ANTAGONISTS HCRTR1, HCRTR2, OXTR ALDH1A1 974/4885TSHR 166/4885HPGD 2392/4885
US-20100105668-A1 Quinazoline derivatives NR1H2, NR1H3, NR3C2 ALDH1A1 2784/4885TSHR 433/4885HPGD 350/4885
US-20180346484-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR3A, HTR5A, HTR3C ALDH1A1 971/4885TSHR 136/4885HPGD 504/4885
US-20120196851-A1 WNT PATHWAY ANTAGONISTS WNT1, WNT3A, CTNNB1 ALDH1A1 1797/4885TSHR 4195/4885HPGD 1628/4885
US-20120065395-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES NR0B1, NR1H3, NCOA3 ALDH1A1 1457/4885TSHR 1119/4885HPGD 580/4885
US-20160207938-A1 QUINAZOLINE DERIVATIVES NR1H2, NR1H3, NR3C2 ALDH1A1 2932/4885TSHR 362/4885HPGD 638/4885
US-11339157-B1 4H-pyrrolo[3,2-c]pyridin-4-one derivatives CYP4B1, CYP2C19, CYP3A4 ALDH1A1 387/4885TSHR 1659/4885HPGD 172/4885
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 ALDH1A1 61/4885TSHR 3483/4885HPGD 389/4885
US-20100197938-A1 Process for producing indole compoud IDO1, IDO2, NOS2 ALDH1A1 2357/4885TSHR 1679/4885HPGD 143/4885
US-20130178505-A1 Compounds for the Inhibition of Cellular Proliferation MKI67, EIF2AK2, CDK2 ALDH1A1 3428/4885TSHR 4098/4885HPGD 2477/4885
US-20100160310-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES NR1H3, NR1H2, NR0B1 ALDH1A1 1741/4885TSHR 1075/4885HPGD 513/4885
US-20070083053-A1 Process for producing indole compound IDO2, IDO1, TDO2 ALDH1A1 2793/4885TSHR 1763/4885HPGD 352/4885
US-20160340331-A1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT HSP90AB1, HSP90AA1, HSP90AB2P ALDH1A1 963/4885TSHR 4447/4885HPGD 1314/4885
US-20110118473-A1 PROCESS FOR CONVERTING 9-DIHYDRO-13ACETYLBACCATIN III PACLITAXEL AND DOCETAXEL H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TUBB6, TUBB3 ALDH1A1 813/4885TSHR 4458/4885HPGD 367/4885
US-20100173913-A1 PYRIDO-AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROLIFERATIVE AGENTS CYP2J2, NR4A1, ALOX15 ALDH1A1 1541/4885TSHR 2961/4885HPGD 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.